FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904609170> ?p ?o ?g. }

• W2904609170 endingPage "37184" @default.
• W2904609170 startingPage "37173" @default.
• W2904609170 abstract "// Sutapa Sinha 1 , Justin C. Boysen 1 , Kari G. Chaffee 2 , Brian F. Kabat 2 , Susan L. Slager 2 , Sameer A. Parikh 1 , Charla R. Secreto 1 , Tim Call 1 , Tait D. Shanafelt 3 , Jose F. Leis 4 , Steven L. Warner 5 , David J. Bearss 5 , Asish K. Ghosh 6 and Neil E. Kay 1 1 Division of Hematology and Mayo Clinic, Rochester, MN, USA 2 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA 3 Department of Medicine-Hematology, Stanford School of Medicine, Stanford, CA, USA 4 Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA 5 Tolero Pharmaceuticals, Inc., Lehi, UT, USA 6 Stephenson Cancer Center and Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA Correspondence to: Neil E. Kay, email: kay.neil@mayo.edu Keywords: AXL; TP-0903; Ibrutinib; CLL; apoptosis Received: September 07, 2018      Accepted: November 16, 2018      Published: December 14, 2018 ABSTRACT Earlier we have shown the expression of a constitutively active receptor tyrosine kinase Axl in CLL B-cells from previously untreated CLL patients, and that Axl inhibitor TP-0903 induces robust leukemic B-cell death. To explore whether Axl is an effective target in relapsed/refractory CLL patients, we analyzed CLL B-cells obtained from CLL patients on ibrutinib therapy. Ibrutinib-exposed CLL B-cells were treated with increasing doses (0.01- 0.50μM) of a new formulation of high-affinity Axl inhibitor, TP-0903 (tartrate salt), for 24 hours and LD 50 doses were determined. Sensitivity of CLL B-cells was compared with known prognostic factors and effect of TP-0903 was also evaluated on Axl signaling pathway in CLL B-cells from this cohort. We detected sustained overexpression of Axl in CLL B-cells from CLL patients on ibrutinib treatment, suggests targeting Axl could be a promising strategy to overcome drug resistance and killing of CLL B-cells in these patients. We found that CLL B-cells from sixty-nine percent of relapsed CLL patients actively on ibrutinib therapy were found to be highly sensitive to TP-0903 with induction of apoptosis at nanomolar doses (≤0.50 μM). TP-0903 treatment effectively inhibited Axl phosphorylation and reduced expression levels of anti-apoptotic proteins (Mcl-1, XIAP) in ibrutinib exposed CLL B-cells. In total, our in vitro preclinical studies showing that TP-0903 is very effective at inducing apoptosis in CLL B-cells obtained from ibrutinib-exposed patients supports further testing of this drug in relapsed/refractory CLL." @default.
• W2904609170 created "2018-12-22" @default.
• W2904609170 creator A5002515721 @default.
• W2904609170 creator A5009747339 @default.
• W2904609170 creator A5025049887 @default.
• W2904609170 creator A5033825180 @default.
• W2904609170 creator A5037979147 @default.
• W2904609170 creator A5041136366 @default.
• W2904609170 creator A5041539604 @default.
• W2904609170 creator A5055924314 @default.
• W2904609170 creator A5065682761 @default.
• W2904609170 creator A5067100969 @default.
• W2904609170 creator A5080387735 @default.
• W2904609170 creator A5085150792 @default.
• W2904609170 creator A5087950597 @default.
• W2904609170 creator A5088390990 @default.
• W2904609170 date "2018-12-14" @default.
• W2904609170 modified "2023-10-16" @default.
• W2904609170 title "Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy" @default.
• W2904609170 cites W1517918365 @default.
• W2904609170 cites W1999128869 @default.
• W2904609170 cites W1999522887 @default.
• W2904609170 cites W2018765113 @default.
• W2904609170 cites W2024216962 @default.
• W2904609170 cites W2036758696 @default.
• W2904609170 cites W2040129575 @default.
• W2904609170 cites W2042748226 @default.
• W2904609170 cites W2067064694 @default.
• W2904609170 cites W2075875145 @default.
• W2904609170 cites W2078626573 @default.
• W2904609170 cites W2088904620 @default.
• W2904609170 cites W2092395234 @default.
• W2904609170 cites W2092810158 @default.
• W2904609170 cites W2128841304 @default.
• W2904609170 cites W2137713702 @default.
• W2904609170 cites W2142099365 @default.
• W2904609170 cites W2160206973 @default.
• W2904609170 cites W2162550834 @default.
• W2904609170 cites W2175330263 @default.
• W2904609170 cites W2179114654 @default.
• W2904609170 cites W2182217094 @default.
• W2904609170 cites W2270313998 @default.
• W2904609170 cites W2369297677 @default.
• W2904609170 cites W2557337948 @default.
• W2904609170 cites W2568917916 @default.
• W2904609170 cites W2737606003 @default.
• W2904609170 cites W2781525129 @default.
• W2904609170 doi "https://doi.org/10.18632/oncotarget.26444" @default.
• W2904609170 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324680" @default.
• W2904609170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30647852" @default.
• W2904609170 hasPublicationYear "2018" @default.
• W2904609170 type Work @default.
• W2904609170 sameAs 2904609170 @default.
• W2904609170 citedByCount "9" @default.
• W2904609170 countsByYear W29046091702019 @default.
• W2904609170 countsByYear W29046091702020 @default.
• W2904609170 countsByYear W29046091702022 @default.
• W2904609170 countsByYear W29046091702023 @default.
• W2904609170 crossrefType "journal-article" @default.
• W2904609170 hasAuthorship W2904609170A5002515721 @default.
• W2904609170 hasAuthorship W2904609170A5009747339 @default.
• W2904609170 hasAuthorship W2904609170A5025049887 @default.
• W2904609170 hasAuthorship W2904609170A5033825180 @default.
• W2904609170 hasAuthorship W2904609170A5037979147 @default.
• W2904609170 hasAuthorship W2904609170A5041136366 @default.
• W2904609170 hasAuthorship W2904609170A5041539604 @default.
• W2904609170 hasAuthorship W2904609170A5055924314 @default.
• W2904609170 hasAuthorship W2904609170A5065682761 @default.
• W2904609170 hasAuthorship W2904609170A5067100969 @default.
• W2904609170 hasAuthorship W2904609170A5080387735 @default.
• W2904609170 hasAuthorship W2904609170A5085150792 @default.
• W2904609170 hasAuthorship W2904609170A5087950597 @default.
• W2904609170 hasAuthorship W2904609170A5088390990 @default.
• W2904609170 hasBestOaLocation W29046091701 @default.
• W2904609170 hasConcept C121608353 @default.
• W2904609170 hasConcept C126322002 @default.
• W2904609170 hasConcept C143998085 @default.
• W2904609170 hasConcept C157333092 @default.
• W2904609170 hasConcept C170493617 @default.
• W2904609170 hasConcept C194409129 @default.
• W2904609170 hasConcept C2777938653 @default.
• W2904609170 hasConcept C2778461978 @default.
• W2904609170 hasConcept C2779675984 @default.
• W2904609170 hasConcept C2779878957 @default.
• W2904609170 hasConcept C42362537 @default.
• W2904609170 hasConcept C502942594 @default.
• W2904609170 hasConcept C5364575 @default.
• W2904609170 hasConcept C71924100 @default.
• W2904609170 hasConceptScore W2904609170C121608353 @default.
• W2904609170 hasConceptScore W2904609170C126322002 @default.
• W2904609170 hasConceptScore W2904609170C143998085 @default.
• W2904609170 hasConceptScore W2904609170C157333092 @default.
• W2904609170 hasConceptScore W2904609170C170493617 @default.
• W2904609170 hasConceptScore W2904609170C194409129 @default.
• W2904609170 hasConceptScore W2904609170C2777938653 @default.
• W2904609170 hasConceptScore W2904609170C2778461978 @default.
• W2904609170 hasConceptScore W2904609170C2779675984 @default.
• W2904609170 hasConceptScore W2904609170C2779878957 @default.

• next